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Introduction
Atrial fibrillation (AF) is a medical condition char-
acterized by chaotic and irregular electrical activ-
ity in the heart’s upper chamber; it is the most 
common heart dysrhythmia diagnosed in the 
United States, affecting 3–5 million individuals.1,2 
Both vitamin K antagonists (VKAs), such as war-
farin, and non-VKA oral anticoagulants (NOACs), 
including apixaban, dabigatran, edoxaban, and 
rivaroxaban, are used in stroke prevention among 
patients with AF.3,4 Comparing efficacy and safety 
profiles across all oral anticoagulants (OACs) is 
challenging since the populations included in the 
pivotal clinical trials remain heterogenous. 
However, the increased risk of bleeding is a major 
concern with all OAC treatments.5
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Abstract
Background: Gastrointestinal (GI) bleeding is the most common type of major bleeding 
associated with oral anticoagulant (OAC) treatment. Patients with major bleeding are at an 
increased risk of a stroke if an OAC is not reinitiated.
Methods: Non-valvular atrial fibrillation (NVAF) patients initiating OACs were identified from 
the Centers for Medicare and Medicaid Services (CMS) Medicare data and four US commercial 
claims databases. Patients who had a major GI bleeding event (hospitalization with primary 
diagnosis of GI bleeding) while on an OAC were selected. A control cohort of patients without 
a major GI bleed during OAC treatment was matched to major GI bleeding patients using 
propensity scores. Stroke/systemic embolism (SE), major bleeding, and mortality (in the CMS 
population) were examined using Cox proportional hazards models with robust sandwich 
estimates.
Results: A total of 15,888 patients with major GI bleeding and 833,052 patients without major 
GI bleeding were included in the study. Within 90 days of the major GI bleed, 58% of patients 
discontinued the initial OAC treatment. Patients with a major GI bleed had a higher risk of 
stroke/SE [hazard ratio (HR): 1.57, 95% confidence interval (CI): 1.42–1.74], major bleeding 
(HR: 2.79, 95% CI: 2.64–2.95), and all-cause mortality (HR: 1.29, 95% CI: 1.23–1.36) than 
patients without a major GI bleed.
Conclusion: Patients with a major GI bleed on OAC had a high rate of OAC discontinuation and 
significantly higher risk of stroke/SE, major bleeding, and mortality after hospital discharge 
than those without. Effective management strategies are needed for patients with risk factors 
for major GI bleeding.
Keywords: atrial fibrillation, gastrointestinal bleeding, major bleeding, oral anticoagulants, 
stroke 
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Gastrointestinal (GI) bleeding is the most com-
mon type of bleeding among OAC-treated non-
valvular AF (NVAF) patients, and it causes 
considerable morbidity and mortality (5–15%), 
which leads to significant health care burden;6,7 
major GI bleeding events occurring after OAC 
treatment initiation have been associated with 
significant 30-day mortality, hospitalization, and 
health care resource utilization.8 A meta-analysis 
of landmark randomized clinical trials (RCTs) 
showed that, as compared with warfarin, while 
NOACs as a class reduce stroke or systemic 
embolism (SE) events by 19% and intracranial 
hemorrhage (ICH) by 52%, each NOAC varies in 
risk of GI bleeding.4
NOACs showed varying comparative risk of GI 
bleeding relative to warfarin in the RCTs. In the 
ARISTOTLE trial, apixaban had similar risk of GI 
bleeding compared with warfarin.9 In the RE-LY 
trial, dabigatran administered at a dose of 150 mg 
BID was associated with a higher risk of GI bleed-
ing [relative risk: 1.50, 95% confidence interval 
(CI): 1.19–1.89] and 110 mg BID was associated 
with a non-significantly different risk of GI bleed-
ing (relative risk: 1.10, 95% CI: 0.86–1.41) com-
pared with warfarin.10 In the ROCKET AF trial, 
major bleeding from a GI site was more common 
in the rivaroxaban group (3.2%) as compared with 
the warfarin group (2.2%).11 The ENGAGE 
AF-TIMI trial provided evidence that low-dose 
(30 mg) edoxaban was associated with a lower risk 
of GI major bleeding by nearly 33%, but high-dose 
edoxaban (60 mg) increased the risk of GI bleeding 
by 23% as compared with warfarin.12 The 2016 
European Society of Cardiology (ESC) guidelines 
for the management of AF recommended that 
patients with high risk of GI bleeding select a VKA 
or another NOAC over dabigatran 150 mg BID, 
rivaroxaban 20 mg QD, or edoxaban 60 mg QD.13
The common sites of GI bleeding differ accord-
ing to specific OACs.14–16 For example, while 
upper GI bleeding predominates in warfarin, 
53% lower GI bleeding was observed in dabi-
gatran users with a major GI bleed; for apixaban 
and rivaroxaban, upper GI bleeding is more com-
mon than lower GI bleeding (apixaban: 63% 
 versus 37%; rivaroxaban: 76% versus 24%); and 
edoxaban showed comparable risks of upper and 
lower GI bleeding.9,12,17,18
Due to the increased risk of bleeding, many 
patients stop OAC treatment after a bleed.19,20 
For patients who have a major bleeding event, the 
ESC guidelines recommend re-initiation of an 
OAC as soon as the cardiovascular thrombotic 
risks associated with discontinuation are thought 
to outweigh the risk of subsequent bleeding.13,21 
If an OAC was not reinitiated after a major GI 
bleed, patients incurred similar or lower risks of 
recurrent GI bleeding events but higher risk of 
thromboembolic events.19,20 Although the bene-
fits of restarting an OAC have been found to out-
weigh the risk of bleeding, 25–50% of patients 
still do not resume an OAC after a GI bleed.19,20
There are limited data regarding OAC use and GI 
bleeding in the real-world clinical setting. In this 
study, we used pooled data of five US claims 
databases to examine the risk of stroke/SE and 
subsequent major bleeding between OAC-treated 
NVAF patients with and without a major GI 
bleeding event. Second, we analyzed event char-
acteristics and post-event OAC treatment pat-
terns among patients with major GI bleeding.
Methods
Five large national claims databases with the lat-
est available data at the time of application were 
pooled in this study. They included 100% fee-
for-service US Centers for Medicare and 
Medicaid Services (CMS) data (1 January 2012–
31 December 2016), the Truven MarketScan® 
Commercial Claims and Encounter (“MarketScan”; 
1 January 2012–31 March 2018), the IMS 
PharMetrics Plus™ Database (“PharMetrics”; 1 
January 2012–30 September 2018), the Optum 
Clinformatics™ Data Mart (“Optum”; 1 January 
2012–30 June 2018), and the Humana Research 
Database (“Humana”; 1 January 2012–30 June 
2018).
More details on the datasets can be found in our 
previous publication.22 Of note, Medicare supple-
mental plans in MarketScan and PharMetrics data 
were not included in the study to avoid potential 
duplicates with Medicare Part A and Part B. 
Details on the pooling method have been pub-
lished in previous articles.22,23
Study design and patient selection
AF patients who were treated with apixaban, dab-
igatran, edoxaban, rivaroxaban, or warfarin were 
selected from each database before pooling. The 
first OAC pharmacy claim date was designated as 
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the initial OAC prescription date. Patients were 
required to be ⩾18 years of age in the commercial 
datasets or ⩾65 years of age in the CMS data and 
had continuous medical and pharmacy health 
plan enrollment for ⩾12 months prior to the ini-
tial OAC prescription date.
Major GI bleeding events were defined as a hos-
pitalization with a primary diagnosis of GI bleed-
ing during the OAC treatment period. For these 
patients, the index date was the date of the first 
major GI bleed hospital discharge date. A control 
cohort of patients without a major GI bleed dur-
ing the initial OAC treatment period was created. 
Selected control cohort patients were randomly 
assigned hypothetical index dates based on the 
distribution of the time from initial OAC pre-
scription to index date in the major GI bleeding 
cohort. The baseline period was defined as 
12 months before the index date.
Patients were excluded from the study if they had 
evidence of valvular heart disease, venous throm-
boembolism, transient AF (pericarditis, hyperthy-
roidism, thyrotoxicosis), or heart valve replacement/
transplant during the baseline period, pregnancy 
during the study period, or hip or knee replace-
ment surgery within 6 weeks prior to the initial 
OAC prescription date. To apply the new-user 
design, this study limited patients to those without 
an OAC prescription within 12 months before the 
initial OAC prescription date.
Among patients with major GI bleed, those who 
died during the hospitalization were excluded 
from the study [290/15,224 (1.9%); patients in 
the MarketScan and PharMetrics data were not 
part of this exclusion due to incomplete mortality 
data]. Furthermore, to evaluate the subsequent 
effectiveness and safety outcomes post-index 
date, patients with a follow-up time equal to zero 
days (minimum follow-up = 1 day) were also 
excluded.
Outcome measures
For patients with a major GI bleed, time to the 
event, length of inpatient stay (LOS) for the 
event, and sites of the major GI bleeding were 
evaluated, as well as related health care costs and 
utilization. Treatment patterns during the 90 days 
after the major GI bleed were also evaluated, 
including initial OAC re-initiation, discontinua-
tion, and switching (between OACs).
Clinical outcomes were compared between OAC 
patients who had a major GI bleed and those who 
did not. Outcomes were evaluated between 1-day 
post-index date to the earliest of death, end of 
continuous medical or pharmacy plan enroll-
ment, or the end of study period (follow-up 
period). Both effectiveness and safety outcomes 
were studied: for the former, stroke/SE included 
ischemic stroke, hemorrhagic stroke, and SE; for 
the latter, major bleeding included GI bleeding, 
ICH, and major bleeding at other key sites. To 
ensure mortality data accuracy, all-cause mortal-
ity was examined only in CMS data as only the 
death information from the CMS data is collected 
and validated from the Social Security 
Administration.
Statistical methods
The incidence of major GI bleeding was evalu-
ated among all OAC-treated patients. Clinical 
characteristics and treatment patterns were exam-
ined descriptively among patients with a major GI 
bleed. To compare clinical outcomes of OAC-
treated patients with and without a major GI 
bleed, baseline clinical characteristics of the two 
cohorts were first evaluated. Propensity score 
matching (PSM)[1:3 (1 for patients with major 
GI bleed and 3 for those without)] was conducted 
within each dataset to adjust for potential con-
founders and balance the cohorts of interest. A 
logistic regression model was used to generate 
propensity scores by predicting the probability of 
having a major GI bleed among patients in both 
cohorts.24 Baseline variables included in the 
model were patient demographics, index OAC 
prescription, Charlson comorbidity index (CCI) 
score,25 major bleeding (GI bleeding, ICH, and 
other major bleeding), non-major bleeding, 
stroke/SE history, comorbidities, co-medications, 
and inpatient and emergency department visits. 
By matching the variables listed above, two well-
balanced cohorts were created and pooled. 
Standardized differences with a threshold of 10% 
were used to denote the statistical and clinical dif-
ferences between the matched cohorts.26
Adjusted comparative clinical outcomes, includ-
ing stroke/SE, major bleeding, and mortality (in 
the CMS population), were examined using Cox 
proportional hazards models with robust sand-
wich estimates.22 In addition to the cohort indi-
cator, any post-PSM variables (i.e. baseline 
major GI bleeding and peptic ulcers) that were 
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imbalanced were added to the models as inde-
pendent covariates. All analyses were conducted 
using SAS 9.4 (Cary, NC, USA).
Institutional review board approval
Since this study did not involve the collection, 
use, or transmittal of individually identifiable 
data, it was deemed exempt from institutional 
review board (IRB) review by Solutions IRB. 
Both the datasets and the security of the offices 
where analysis was completed (and where the 
datasets are kept) meet the requirements of the 
Health Insurance Portability and Accountability 
Act of 1996. Solutions IRB determined this study 
to be EXEMPT from the Office for Human 
Research Protections (OHRP)’s Regulations for 
the Protection of Human Subjects (45 CFR 46) 
under Exemption 4: Research involving the col-
lection or study of existing data, documents, 
records, pathological specimens, or diagnostic 
specimens, if these sources are publicly available 
or if the information is recorded by the investiga-
tor in such a manner that subjects cannot be 
identified, directly or through identifiers linked 
to the subjects. The HIPAA Authorization 
Waiver was granted in accordance with the speci-
fications of 45 CFR 164.512(i). This project was 
conducted in full accordance with all applicable 
laws and regulations, and adhered to the project 
plan that was reviewed by Solutions IRB. 
Informed consent from subjects included in this 
study is considered exempt under 45 CFR 
46.116(d), which states that the IRB was satis-
fied that the research presents minimal risk (no 
risks of harm, considering probability and magni-
tude, greater than those ordinarily encountered 
in daily life or during the performance of routine 
examinations or tests); and the waiver or altera-
tion will not adversely affect the rights and wel-
fare of the subjects; and the research could not 
practicably be carried out without the waiver or 
alteration; and whenever appropriate, the sub-
jects will be provided with additional pertinent 
information after participation.
Results
A total of 848,940 OAC-treated NVAF patients 
were eligible per the selection criteria, including 
15,888 patients with major GI bleeding and 833,052 
patients without major GI bleeding (Figure 1).
Major GI bleeding events
After applying the patient selection criteria, among 
all OAC-treated patients, the incidence rate of 
major GI bleeding was 2.50 per 100 person-years. 
After initiation of treatment, the unadjusted inci-
dence rates of the initial major GI bleed were 1.8 
(apixaban), 2.2 (dabigatran), 2.0 (edoxaban), 2.8 
(rivaroxaban), and 3.0 (warfarin) per 100 person-
years. The mean time from the initial OAC pre-
scription to the major GI bleeding event was 
78.3 days (median = 40 days; Supplemental mate-
rial Figure 1 online). For the major GI bleeding 
events, the mean hospitalization LOS was 4.4 days, 
with a mean cost of US$11,550; 26%, 24%, and 
1% of patients had diagnosis codes for upper, 
lower, and both upper and lower GI bleeding, 
respectively. The remaining 49% of patients had 
diagnosis codes for unspecified GI bleeding. 
During the hospitalizations for the major GI 
bleeding events, 40% of patients were admitted to 
the intensive care unit, 66% had a blood transfu-
sion, and many underwent esophagogastroduo-
denoscopy (41%) or colonoscopy (18%; Table 1).
OAC treatment patterns after the major  
GI bleed
For patients with major GI bleeding, 3442 (22%) 
had apixaban, 822 (5%) had dabigatran, 5065 
(32%) had rivaroxaban, and 6542 (41%) had 
warfarin as the initial treatment (Supplemental 
Table 1). Within 90 days after the major GI bleed, 
58% of patients discontinued the initial OAC 
treatment. Only 37% of patients re-initiated the 
same OAC treatment as before the major GI 
bleed and 5% switched to another OAC. Among 
patients re-initiating the previous OAC treat-
ment, a small percentage of patients changed to a 
different dose (5%; Table 1).
Patient characteristics and clinical outcomes
When comparing patient characteristics before 
PSM, major GI bleeding patients were older and 
had higher CCI, CHA2DS2-VASc, and HAS-
BLED scores compared with non-major GI bleed-
ing patients. Patients with major GI bleeding also 
had a higher percentage of baseline major and 
non-major bleeding history, comorbidities (such 
as hypertension, coronary artery disease, and con-
gestive heart failure), and majority of the concom-
itant medication use (Supplemental Table 1). 
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Supplemental Table 2 includes the baseline char-
acteristics of the major GI bleeding cohort strati-
fied by initial treatment type.
The pre-PSM unadjusted incidence rate of stroke/
SE was 4.0 for the major GI bleeding cohort and 
1.6 for the non-major GI bleeding cohort, and the 
unadjusted incidence rate of major bleeding was 
18.4 for the major GI bleeding and 3.0 for the 
non-major GI bleeding cohort (per 100 person-
years). (Supplemental Table 1).
A total of 34,143 patients without major GI 
bleeding and 11,381 patients with major GI 
bleeding were matched with a mean follow-up of 
16–17 months (Table 2). Patient characteristics 
were balanced except for baseline major GI bleed-
ing and peptic ulcers (Tables 2 and 3), which 
were adjusted for in the Cox proportional hazards 
models. The cumulative incidence of stroke/SE 
and major bleeding in the post-PSM population 
is shown in Kaplan–Meier curves (Figure 2).
After further adjusting for baseline major GI 
bleeding and peptic ulcers in the Cox models, 
patients with a major GI bleed had a higher risk of 
stroke/SE [hazard ratio (HR): 1.57, 95% confi-
dence interval (CI): 1.42–1.74] and major 
Figure 1. Patient selection criteria.
AF, atrial fibrillation; GI, gastrointestinal; ICD-9/10-CM, International Classification of Diseases – 9th/10th Revision – Clinical 
Modification; OAC, oral anticoagulant; VTE, venous thromboembolism.
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bleeding (HR: 2.79, 95% CI: 2.64–2.95) than 
patients without a major GI bleed (Figure 3). The 
associated risk of stroke/SE was mostly driven by 
ischemic stroke, whereas the risk of major bleed-
ing was mostly driven by GI bleeding.
In the CMS population, the major GI bleeding 
cohort also had a higher risk of all-cause mortality 
(HR: 1.29, 95% CI: 1.23–1.36) compared with 
the non-major GI bleeding cohort (Supplemental 
Table 3).
Table 1. Characteristics of major GI bleeding and treatment patterns after major GI bleeding.
Patients with major GI bleeding (N = 15,888)
 n/mean %/SD
Major GI bleeding inpatient length of stay (in days) 4.4 7.7
Major GI bleeding inpatient stay costs $11,550 $15,839
Major GI bleeding site* 15,888 100.0%
Gastroduodenal site 3738 23.5%
Esophageal site 180 1.1%
Upper GI and unspecified upper GI only 4206 26.5%
Lower GI site only 3760 23.7%
Both upper and lower GI sites 114 0.7%
Unspecified GI site 7808 49.1%
Ulcer 1873 11.8%
Perforation 15 0.1%
Selected healthcare resource use 13,523 85.1%
Colonoscopy 2812 17.7%
Esophagogastroduodenoscopy 6522 41.0%
Capsule endoscopy 82 0.5%
Blood transfusion 10,444 65.7%
Fresh-frozen plasma 433 2.7%
Intensive care unit stay 6421 40.4%




Restarting of the same OAC† 5861 36.9%
Days-to-restarting 29.3 22.1
Dose change†,‡ 296 5.1%
*The categories for major GI bleeding site are not mutually exclusive.
†Measured within 90 days after the major GI bleed.
‡Among patients that restarted OAC treatment.
GI, gastrointestinal, OAC, oral anticoagulant; SD, standard deviation.
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Table 2. Baseline demographics, index drug, healthcare utilization, and follow-up time for patients with and without major GI 
bleeding post propensity score matching.
Non-major GI bleeding cohort (N = 34,143) Major GI bleeding cohort (N = 11,381)
 n/mean %/SD n/mean %/SD STD
Age* 78.3 9.0 78.4 9.2 1.7
 18–54 319 0.9% 104 0.9% 0.2
 55–64 1407 4.1% 529 4.6% 2.6
 65–74 9485 27.8% 3178 27.9% 0.3
 75–79 7270 21.3% 2417 21.2% 0.1
 ⩾80 15,662 45.9% 5153 45.3% 1.2
Female* 17,715 51.9% 5796 50.9% 1.9
U.S. geographic region*
 Northeast 6059 17.7% 2022 17.8% 0.1
 Midwest 9110 26.7% 3004 26.4% 0.7
 South 14,007 41.0% 4691 41.2% 0.4
 West 4886 14.3% 1643 14.4% 0.4
 Other/unknown 81 0.2% 21 0.2% 1.1
Index drug*
 Apixaban 8037 23.5% 2684 23.6% 0.1
 Dabigatran 1703 5.0% 604 5.3% 1.4
 Edoxaban 45 0.1% <11 <0.09% 1.3
 Rivaroxaban 10,638 31.2% 3322 29.2% 4.3
 Warfarin 13,720 40.2% 4761 41.8% 3.4
Baseline all-cause health care utilization (before index admission/index date)
 Inpatient admission visit* 23,173 67.9% 7982 70.1% 4.9
 Outpatient hospital visit 32,503 95.2% 10,831 95.2% 0.1
 ER visit* 19,617 57.5% 6607 58.1% 1.2
 Office visit 33,762 98.9% 11,222 98.6% 2.5
 Pharmacy claim 34,143 100.0% 11,379 100.0% 1.9
Follow-up time (in days) 522.2 429.5 493.6 405.8 6.9
 Median 424 397  
*Variables included in the propensity score matching.
ER, emergency room; GI, gastrointestinal; SD, standard deviation; STD, standardized difference.
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Table 3. Baseline clinical characteristics for patients with and without major GI bleeding post propensity score matching.
Non-major GI bleeding 
cohort (N = 34,143)
Major GI bleeding 
cohort (N = 11,381)
 n/mean %/SD n/mean %/SD STD
Baseline comorbidity
 Charlson comorbidity index* 5.3 3.2 5.4 3.2 2.1
 CHA2DS2-VASc score 5.4 1.8 5.4 1.7 0.9
 HAS-BLED score 4.3 1.1 4.4 1.0 11.9
 History of stroke/SE* 6789 19.9% 2305 20.3% 0.9
 Stroke/SE hospitalization 2307 6.8% 782 6.9% 0.5
 History of bleeding (before index date/index admission) 15,422 45.2% 5512 48.4% 6.5
  Major bleeding hospitalization (before index date/index 
admission)
2738 8.0% 1295 11.4% 11.4
 Major GI bleeding* 1342 3.9% 812 7.1% 14.0
 ICH* 151 0.4% 48 0.4% 0.3
 Other major bleeding* 1490 4.4% 565 5.0% 2.8
 History of non-major bleeding* 12,684 37.1% 4217 37.1% 0.2
 Myocardial infarction* 9106 26.7% 3036 26.7% 0.0
 Renal disease* 16,462 48.2% 5473 48.1% 0.3
 Liver disease* 3772 11.0% 1300 11.4% 1.2
 Dyspepsia or stomach discomfort* 13,569 39.7% 4595 40.4% 1.3
 Diabetes mellitus* 16,511 48.4% 5557 48.8% 0.9
 Hypertension* 32,959 96.5% 11,045 97.0% 2.9
 Congestive heart failure* 20,182 59.1% 6602 58.0% 2.2
 Non-stroke/SE peripheral vascular disease* 14,466 42.4% 4893 43.0% 1.3
 Transient ischemic attack* 5235 15.3% 1771 15.6% 0.6
 Anemia and coagulation defects* 31,217 91.4% 10,314 90.6% 2.8
 Peripheral artery disease 14,125 41.4% 4811 42.3% 1.8
 Coronary artery disease 22,454 65.8% 7691 67.6% 3.8
 CABG/PCI 2110 6.2% 723 6.4% 0.7
 Helicobacter pylori* 541 1.6% 191 1.7% 0.7
 Diverticulosis* 13,623 39.9% 4413 38.8% 2.3
 Peptic ulcers* 4238 12.4% 1812 15.9% 10.1
 Ulcerative colitis* 538 1.6% 216 1.9% 2.5
 GI cancer (stomach, colon, esophageal, and rectal cancer)* 1239 3.6% 429 3.8% 0.7
 Pulmonary disease* 22,568 66.1% 7429 65.3% 1.7
 Esophagitis* 3135 9.2% 1205 10.6% 4.7
(Continued)
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Non-major GI bleeding 
cohort (N = 34,143)
Major GI bleeding 
cohort (N = 11,381)
 n/mean %/SD n/mean %/SD STD
 Esophageal varices* 230 0.7% 91 0.8% 1.5
 Gastritis* 8961 26.2% 3191 28.0% 4.0
 Colonic or rectal ulcer* 140 0.4% 67 0.6% 2.5
 Hemorrhoids* 6743 19.7% 2331 20.5% 1.8
 Mallory–Weiss syndrome* 93 0.3% 58 0.5% 3.8
 Ischemic colitis* 353 1.0% 133 1.2% 1.3
Baseline medication use*
 ACEs/ARBs 22,173 64.9% 7475 65.7% 1.6
 Amiodarone 6683 19.6% 2199 19.3% 0.6
 Beta blockers 21,834 63.9% 7265 63.8% 0.2
 H2-receptor antagonist 3450 10.1% 1172 10.3% 0.6
 Proton pump inhibitor 18,156 53.2% 6295 55.3% 4.3
 Statins 22,916 67.1% 7655 67.3% 0.3
 Antiplatelets 9109 26.7% 3113 27.4% 1.5
 NSAIDs 7104 20.8% 2410 21.2% 0.9
 Inhibitors of warfarin 29,521 86.5% 9849 86.5% 0.2
 Inducers of warfarin 16,315 47.8% 5531 48.6% 1.6
 Dronedarone 1191 3.5% 346 3.0% 2.5
 Digoxin 4778 14.0% 1544 13.6% 1.2
 Calcium channel blockers 17,470 51.2% 5887 51.7% 1.1
 Renin–angiotensin system antagonists 22,954 67.2% 7732 67.9% 1.5
 Glucocorticoids 19,017 55.7% 6348 55.8% 0.2
 Diuretics 23,595 69.1% 7868 69.1% 0.1
 Metformin 6320 18.5% 2125 18.7% 0.4
 Sulfonylureas 4351 12.7% 1415 12.4% 0.9
 Thiazolidinedione 676 2.0% 233 2.0% 0.5
 Insulin 5303 15.5% 1799 15.8% 0.8
 Other diabetes drugs 2387 7.0% 796 7.0% 0.0
 Antiulcer agents 17,507 51.3% 6064 53.3% 4.0
 Antidepressant 11,791 34.5% 4005 35.2% 1.4
*Variables included in the propensity score matching.
ACE/ARB, angiotensin converting enzyme inhibitor/angiotensin-receptor blocker; CABG/PCI, coronary artery bypass grafting/percutaneous 
coronary intervention; GI, gastrointestinal; ICH, intracranial hemorrhage; NSAID, non-steroidal anti-inflammatory drug; SD, standard deviation;  
SE, systemic embolism; STD, standardized difference.
Table 3. (Continued)
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Discussion
This study analyzed pooled data from five US 
national claims datasets, including both Medicare 
enrollees and the commercially insured. To our 
best knowledge, it is the largest real-world study 
to assess the characteristics and consequence of 
major GI bleeding events and subsequent treat-
ment patterns among OAC-treated NVAF 
patients. Over half of patients with a major GI 
bleed discontinued OAC treatment within 90 days 
after hospital discharge from the event. Second, 
when compared with OAC-treated patients with-
out a major GI bleed, those with a major GI bleed 
had a significantly higher risk of subsequent 
stroke/SE and of major bleeding after hospital 
discharge. The risk of mortality was also higher 
for patients with a major GI bleed in the CMS 
population.
In the pivotal RCTs for NOACs and warfarin 
among AF patients, GI bleeding was the most 
prevalent type of major bleeding after OAC treat-
ment: among the enrolled NOAC treated patients, 
3.6–6.2% had overall major bleeding and 1.2–
3.2% had major GI bleeding.10–12,27 Various real-
world studies have also examined the risk of GI 
bleeding among OAC-treated NVAF patients, 
with findings regarding prevalence of GI bleeding 
Figure 3. Propensity score matched incidence rates and hazard ratios of stroke/SE and major bleeding for 
patients with and without major GI bleeding.
Note. Major GI bleeding and peptic ulcers were included as covariates in the Cox proportional hazards models as they were 
unbalanced after propensity score matching.
CI, confidence interval; GI, gastrointestinal; ICH, intracranial hemorrhage; SE, systemic embolism.
Figure 2. Kaplan–Meier curves for stroke/systemic embolism and major bleeding for patients with and 
without major GI bleeding in the propensity score matched population.
GI, gastrointestinal.
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and comparative risk that are generally consistent 
with the abovementioned RCTs.28,29 Similarly, in 
our study, 1.9% (15,888) of selected NVAF 
patients (N = 848,940) had a major GI bleed.
Despite the clinical evidence and ESC guide-
lines,22 more than half of the patients in our study 
were found to have discontinued their OAC treat-
ment after a major GI bleed. Similar to our find-
ings, Hernandez et al.30 reported a less than 50% 
re-initiation rate of OACs after a major hemor-
rhage in the Medicare population from 2010 to 
2012. However, in multiple studies OAC re-initi-
ation has been found to be associated with a lower 
risk of stroke and all-cause mortality than OAC 
discontinuation.30–33 Furthermore, two meta-
analyses concluded that among OAC-treated 
NVAF patients with a major bleed, restarting 
OAC therapy afterwards was associated with a 
reduced risk of stroke and mortality without 
increasing the risk of subsequent bleeding.33,34 
While our study did not evaluate the impact of 
restarting OACs on subsequent events after the 
major GI bleed, the higher stroke/SE risk may be 
related to the high OAC discontinuation rate after 
the index major GI bleeding event. The higher 
subsequent risk for both stroke/SE and major 
bleeding among those with an index major GI 
bleed compared with those without indicates seri-
ous consequences of a major GI bleed. These 
findings also raise the importance of evaluating 
the risk of stroke/SE and bleeding associated with 
OAC treatments and of restarting OACs among 
patients with a major GI bleed.
The importance of minimizing major GI bleeding 
among OAC-treated NVAF patients warrants 
further study in this area. This study leveraged 
data from five large, nationally-representative 
insured populations to examine relevant real-
world associations regarding OAC treatment and 
major GI bleeding. The study’s analysis of clinical 
characteristics, treatment patterns, and follow-up 
risk of stroke/SE and major bleeding provides an 
overall picture about the burden of major GI 
bleeding and current clinical practice patterns 
after a major GI bleeding among OAC-treated 
NVAF patients. Moreover, given that major GI 
bleeding is the most common type of bleeding 
among OAC-treated NVAF patients, the infor-
mation regarding clinical characteristics and asso-
ciated comparative subsequent risk of stroke/SE 
and major bleeding may be important for AF 
management decision-making.
Limitations
Despite its novelty and sufficient statistical power, 
this study has several limitations. For instance, 
the observational retrospective study design is 
limited to observation of associations as opposed 
to inference of causal relationships. Although 
PSM was conducted to adjust for a comprehen-
sive list of covariates when comparing patients 
with and without major GI bleeding, some resid-
ual confounding is still expected.
Additionally, the use of insurance claims data 
may have introduced bias into the study. For 
example, information on drug administration in 
the inpatient setting is unavailable in claims data, 
so only outpatient prescription information was 
available for treatment pattern analysis. Hence, 
patients who opted out of treatment or extended 
the drug use prior to or after the index hospitali-
zation may have been misclassified. Similarly, 
prescription claims cannot capture information 
on whether the medication was administered as 
prescribed or at all and claims data cannot cap-
ture certain clinical parameters. Claims data may 
also have coding errors and lack clinical adjudica-
tion, resulting in inaccurate diagnoses or proce-
dure codes that were used to measure the 
outcomes. Finally, the results may not be general-
izable to the overall NVAF population in the 
United States because the study did not include 
uninsured patients or patients solely covered by 
public health insurance plans other than the 
Medicare.
Conclusion
OAC-treated NVAF patients who had a major GI 
bleeding event were more likely to develop recur-
rent major bleeding and subsequent stroke/SE 
compared with those without a major GI bleed. 
Over 50% of patients discontinued their OAC 
within 90 days after discharge from hospitaliza-
tion for a major GI bleed; therefore, future analy-
sis is needed to determine the impact of treatment 
discontinuation on clinical outcomes. Given the 
serious consequences of major GI bleeding among 
OAC-treated NVAF patients, more research is 
needed to identify effective management strate-
gies for these high-risk patients that can minimize 
major GI bleeding in this patient population.
Conflict of interest statement
S Deitelzweig is a consultant for Bristol Myers 
Squibb Company/Pfizer Inc., Daiichi-Sankyo, 
Therapeutic Advances in Gastroenterology 14
12 journals.sagepub.com/home/tag
Portola, and Boehringer Ingelheim, and has been 
on the speakers’ bureau for Bristol Myers Squibb 
Company/Pfizer Inc., and Boehringer Ingelheim.
A Keshishian is a paid employee of STATinMED 
Research which is a paid consultant to Pfizer Inc. 
and Bristol-Myers Squibb Company.
A Kang, A Dhamane, N Balachander, L 
Rosenblatt, and J Jiang are paid employees and 
shareholders of Bristol-Myers Squibb Company.
X Luo and J Mardekian are paid employees and 
shareholders of Pfizer, Inc.
GYH Lip is a consultant for Bayer/Janssen, BMS/
Pfizer, Medtronic, Boehringer Ingelheim, 
Novartis, Verseon and Daiichi-Sankyo. Speaker 
for Bayer, BMS/Pfizer, Medtronic, Boehringer 
Ingelheim, and Daiichi-Sankyo. No fees are 
directly received personally.
Funding
The authors disclosed receipt of the following 
financial support for the research, authorship, 
and/or publication of this article: This study was 
funded by Bristol-Myers Squibb Company and 
Pfizer, Inc.
ORCID iD
Allison Keshishian  https://orcid.org/0000- 
0002-9986-1227
Supplemental material
Supplemental material for this article is available 
online.
References
 1. Shea JB and Sears SF. Cardiology patient pages. 
A patient’s guide to living with atrial fibrillation. 
Circulation 2008; 117: e340–e343.
 2. Colilla S, Crow A, Petkun W, et al. Estimates of 
current and future incidence and prevalence of 
atrial fibrillation in the US adult population. Am J 
Cardiol 2013; 112: 1142–1147.
 3. Hart RG, Pearce LA and Aguilar MI. Meta-
analysis: antithrombotic therapy to prevent 
stroke in patients who have nonvalvular atrial 
fibrillation. Ann Intern Med 2007; 146: 857–867.
 4. Ruff CT, Giugliano RP, Braunwald E, et al. 
Comparison of the efficacy and safety of new 
oral anticoagulants with warfarin in patients with 
atrial fibrillation: a meta-analysis of randomised 
trials. Lancet 2014; 383: 955–962.
 5. Hansen ML, Sørensen R, Clausen MT, et al. 
Risk of bleeding with single, dual, or triple 
therapy with warfarin, aspirin, and clopidogrel in 
patients with atrial fibrillation. Arch Intern Med 
2010; 170: 1433–1441.
 6. Sam C, Massaro JM, D’Agostino RB Sr, et al. 
Warfarin and aspirin use and the predictors of 
major bleeding complications in atrial fibrillation 
(the Framingham Heart Study). Am J Cardiol 
2004; 94: 947–951.
 7. Lanas A, Garcia-Rodriguez LA, Polo-Tomas 
M, et al. Time trends and impact of upper and 
lower gastrointestinal bleeding and perforation in 
clinical practice. Am J Gastroenterol 2009; 104: 
1633–1641.
 8. Abraham NS and Castillo DL. Novel 
anticoagulants: bleeding risk and management 
strategies. Curr Opin Gastroenterol 2013; 29: 
676–683.
 9.  Hylek EM, Held C, Alexander JH, et al. Major 
bleeding in patients with atrial fibrillation 
receiving apixaban or warfarin: the ARISTOTLE 
trial (apixaban for reduction in stroke and other 
thromboembolic events in atrial fibrillation): 
predictors, characteristics, and clinical outcomes. 
J Am Coll Cardiol 2014; 63: 2141–2147.
 10.  Connolly SJ, Ezekowitz MD, Yusuf S, et al. 
Dabigatran versus warfarin in patients with  
atrial fibrillation. N Engl J Med 2009; 361: 
1139–1151.
 11. Patel MR, Mahaffey KW, Garg J, et al. 
Rivaroxaban versus warfarin in nonvalvular atrial 
fibrillation. N Engl J Med 2011; 365: 883–891.
 12. Giugliano RP, Ruff CT, Braunwald E, et al. 
Edoxaban versus warfarin in patients with atrial 
fibrillation. N Engl J Med 2013; 369: 2093–2104.
 13. Kirchhof P, Benussi S, Kotecha D, et al. 2016 
ESC guidelines for the management of atrial 
fibrillation developed in collaboration with 
EACTS. Eur J Cardiothorac Surg 2016; 50: 
e1–e88.
 14. Desai J, Kolb JM, Weitz JI, et al. Gastrointestinal 
bleeding with the new oral anticoagulants—
defining the issues and the management 
strategies. Thromb Haemost 2013; 110: 205–212.
 15. Heidbuchel H, Verhamme P, Alings M, et al. 
Updated European heart rhythm association 
practical guide on the use of non-vitamin K 
antagonist anticoagulants in patients with 
nonvalvular atrial fibrillation. Europace 2015; 17: 
1467–1507.
 16. Cheung KS and Leung WK. Gastrointestinal 
bleeding in patients on novel oral anticoagulants: 
S Deitelzweig, A Keshishian et al.
journals.sagepub.com/home/tag 13
risk, prevention and management. World J 
Gastroenterol 2017; 23: 1954.
 17. Eikelboom JW, Wallentin L, Connolly SJ, et al. 
Risk of bleeding with 2 doses of dabigatran 
compared with warfarin in older and younger 
patients with atrial fibrillation: an analysis of the 
randomized evaluation of long-term anticoagulant 
therapy (RE-LY) trial. Circulation 2011; 123: 
2363–2372.
 18. Piccini JP, Garg J, Patel MR, et al. Management 
of major bleeding events in patients treated 
with rivaroxaban vs. warfarin: results from 
the ROCKET AF trial. Eur Heart J 2014; 35: 
1873–1880.
 19. Qureshi W, Mittal C, Patsias I, et al. Restarting 
anticoagulation and outcomes after major 
gastrointestinal bleeding in atrial fibrillation. Am 
J Cardiol 2014; 113: 662–668.
 20. Staerk L, Lip GY, Olesen JB, et al. Stroke 
and recurrent haemorrhage associated with 
antithrombotic treatment after gastrointestinal 
bleeding in patients with atrial fibrillation: 
Nationwide cohort study. BMJ 2015; 351: h5876.
 21. Halvorsen S, Storey RF, Rocca B, et al. 
Management of antithrombotic therapy after 
bleeding in patients with coronary artery disease 
and/or atrial fibrillation: expert consensus paper 
of the European society of cardiology working 
group on thrombosis. Eur Heart J 2017; 38: 
1455–1462.
 22. Lip GY, Keshishian A, Li X, et al. Effectiveness 
and safety of oral anticoagulants among 
nonvalvular atrial fibrillation patients: the 
ARISTOPHANES study. Stroke 2018; 49: 
2933–2944.
 23. Li X, Deitelzweig S, Keshishian A, et al. 
Effectiveness and safety of apixaban versus 
warfarin in non-valvular atrial fibrillation patients 
in “real-world” clinical practice. Thromb Haemost 
2017; 117: 1072–1082.
 24. Austin PC. The use of propensity score methods 
with survival or time-to-event outcomes: 
reporting measures of effect similar to those used 
in randomized experiments. Stat Med 2014; 33: 
1242–1258.
 25. Charlson ME, Pompei P, Ales KL, et al. A new 
method of classifying prognostic comorbidity in 
longitudinal studies: development and validation. 
J Chronic Dis 1987; 40: 373–383.
 26. Austin PC. Balance diagnostics for comparing 
the distribution of baseline covariates between 
treatment groups in propensity-score matched 
samples. Stat Med 2009; 28: 3083–3107.
 27. Granger CB, Alexander JH, McMurray JJ, et al. 
Apixaban versus warfarin in patients with atrial 
fibrillation. N Engl J Med 2011; 365: 981–992.
 28. Ntaios G, Papavasileiou V, Makaritsis K, et al. 
Real-world setting comparison of nonvitamin-K 
antagonist oral anticoagulants versus vitamin-K 
antagonists for stroke prevention in atrial 
fibrillation: a systematic review and meta-analysis. 
Stroke 2017; 48: 2494–2503.
 29. Deitelzweig S, Farmer C, Luo X, et al. Risk of 
major bleeding in patients with non-valvular 
atrial fibrillation treated with oral anticoagulants: 
a systematic review of real-world observational 
studies. Curr Med Res Opin 2017; 33: 1583–1594.
 30. Hernandez I, Zhang Y, Brooks MM, et al. 
Anticoagulation use and clinical outcomes after 
major bleeding on dabigatran or warfarin in atrial 
fibrillation. Stroke 2017; 48: 159–166.
 31. Staerk L, Lip GY, Olesen JB, et al. Stroke 
and recurrent haemorrhage associated with 
antithrombotic treatment after gastrointestinal 
bleeding in patients with atrial fibrillation: 
nationwide cohort study. BMJ 2015; 351: h5876.
 32. Sengupta N, Marshall AL, Jones BA, et al. 
Rebleeding vs thromboembolism after 
hospitalization for gastrointestinal bleeding 
in patients on direct oral anticoagulants. Clin 
Gastroenterol Hepatol 2018; 16: 1893–1900.
 33. Proietti M, Romiti GF, Romanazzi I, et al. 
Restarting oral anticoagulant therapy after major 
bleeding in atrial fibrillation: a systematic review 
and meta-analysis. Int J Cardiol 2018; 261: 84–91.
 34. Zhou Y, Guo Y, Liu D, et al. Restarting of 
anticoagulation in patients with atrial fibrillation 
after major bleeding: a meta-analysis. J Clin 
Pharm Ther 2020; 45: 591–601.
Visit SAGE journals online 
journals.sagepub.com/
home/tag
SAGE journals
